Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
(MEASURE Trial)
Recruiting in Palo Alto (17 mi)
+17 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Center for International Blood and Marrow Transplant Research
No Placebo Group
Trial Summary
What is the purpose of this trial?
Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).
Eligibility Criteria
Inclusion Criteria
Complete remission (CR) definition per local institutional criteria
Has specimen from time of AML diagnosis available
Provision of signed and dated informed consent form
See 6 more
Treatment Details
Interventions
- Prospective determination of the clinical utility of measurable residual disease (MRD) testing (Other)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Adult patients with AML in complete remission undergoing alloHCTExperimental Treatment1 Intervention
Adult patients with AML in complete remission undergoing alloHCT
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
University of ColoradoAurora, CO
Vanderbilt University Medical CenterNashville, TN
Cleveland ClinicCleveland, OH
The Ohio State University Comprehensive Cancer CenterColumbus, OH
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Center for International Blood and Marrow Transplant ResearchLead Sponsor
National Marrow Donor ProgramCollaborator